India is soon going to start trial on world’s first “Made in India” Leprosy Vaccine and will pilot it in five districts of Bihar and Gujarat.
Around 60% of the global leprosy patients live in India as delay in detection and treatment leaves many crippled for life.
Looking at how patients respond in the pilot phase, the government plans to implement the programme in other high-prevalence districts across the country.
If the response in these areas gives a satisfactory result, the trial would be considered a success and given to more people across the country.
Representational Image AP
According to Union health minister Jagat Prakash Nadda, the Centre has already started door-to-door screening in 50 high-prevalence districts across the country and over 7.5 crore people have been screened.